- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07623837
Clinical Validation of AI-Based Quantitative Eye Movement Analysis From Smartphone 9-Gaze Videos (Glandy EOM) (GLANDY-EOM-VAL)
Prospective Multicenter Observational Study for Clinical Validation of AI-Based Quantitative Eye Movement Analysis Using Smartphone-Recorded 9-Gaze Videos
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Ocular motility is commonly evaluated using the 9-gaze examination, which relies on clinician observation and semi-quantitative grading. This approach is inherently subjective and can show inter-observer variability and limited sensitivity to subtle changes over time. Objective, quantitative assessment of eye movement remains an unmet clinical need, particularly for monitoring disease progression and treatment response.
Recent advances in artificial intelligence have enabled automated analysis of facial and ocular features from smartphone-recorded videos, offering the potential for reproducible quantitative measurement of eye movement. Glandy EOM is an investigational software-only medical device (SaMD) developed by THYROSCOPE INC. that processes smartphone-recorded 9-gaze videos to generate quantitative eye movement metrics. Glandy EOM has not yet received regulatory approval and is used for research purposes only in this study.
The study is a prospective, multicenter, multinational observational investigation designed to evaluate the clinical validity of Glandy EOM. The study population consists of adults with suspected or confirmed ocular motility abnormalities; healthy volunteers without any clinical indication for 9-gaze examination are not enrolled. Because eligibility is based on clinical suspicion or diagnosis of ocular motility abnormality rather than confirmed disease at enrollment, some participants may ultimately be clinically judged to have no abnormality on formal evaluation; such subjects remain part of the study population. Participants will undergo a single study visit consisting of (1) a standard clinical 9-gaze examination with clinician grading (-4 to +4), (2) a smartphone video recording performed with the assistance of a trained operator using a standardized setup, and (3) a patient self-recorded smartphone video acquired through the study mobile application.
For quantitative reference measurements, independent rater-derived measurements will be obtained from the recorded videos using a calibrated reference approach. A calibration marker of known size will be placed on the glabella during video acquisition to enable real-world scale estimation for the reference measurements. The calibration marker is used only for rater-based reference measurement and is not used by the AI algorithm.
The primary objective is to evaluate agreement between AI-derived quantitative eye movement metrics and rater-derived measurements of corneal center displacement, expressed as distance (mm) and angular deviation. Secondary objectives are to evaluate correlation between AI-derived metrics and clinician-assessed 9-gaze grading, and to evaluate whether AI-derived metrics obtained from patient self-recorded videos are comparable to those obtained from assistant-aided recordings. The investigational device is used solely for video acquisition and analysis and does not influence clinical decision-making during the study.
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienkontakt
- Name: Jaemin Park
- Telefonnummer: +82-52-264-4154
- E-Mail: jaemin.park@thyroscope.com
Studienorte
-
-
California
-
San Jose, California, Vereinigte Staaten, 95134
- 3003 North First Street #221
-
Kontakt:
- Jaemin Park
- Telefonnummer: +82-52-264-4154
- E-Mail: jaemin.park@thyroscope.com
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Probenahmeverfahren
Studienpopulation
Adults of legal age of consent with suspected or confirmed ocular motility abnormalities, recruited at participating ophthalmology sites.
Some enrolled participants may ultimately be clinically judged to have no abnormality on formal evaluation; these subjects remain part of the study population and are not considered healthy volunteers.
Beschreibung
Inclusion Criteria:
- Adults who have reached the legal age of consent for research participation in the applicable jurisdiction.
- Subjects with suspected or known ocular motility abnormalities.
- Subjects who are able to understand and follow gaze instructions required for the 9-gaze examination, as judged by the investigator.
- Subjects who are able to undergo facial video recording using a smartphone.
- Subjects who provide written informed consent.
Exclusion Criteria:
- Conditions that prevent reliable detection of ocular landmarks in video recordings (e.g., severe ptosis, corneal opacity, or significant occlusion of the eyes).
- Ocular or facial conditions that, in the opinion of the investigator, may significantly interfere with image-based analysis.
- Subjects who are unable to comply with study procedures.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
Ocular motility abnormality cohort (single cohort)
Adults with suspected or confirmed ocular motility abnormalities scheduled for clinical 9-gaze examination at participating ophthalmology sites.
No separate healthy-volunteer control cohort is enrolled; some participants may ultimately be clinically judged to have no abnormality on formal evaluation but remain part of the study population.
|
Glandy EOM is an investigational software-only medical device developed by THYROSCOPE INC. It has not yet received regulatory approval and is used for research purposes only in this study. Glandy EOM processes smartphone-recorded 9-gaze facial videos to generate AI-derived quantitative eye movement metrics:
AI outputs are generated for research analysis and are NOT used to guide real-time clinical decisions during the study. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Agreement between AI-derived and rater-derived corneal center displacement (distance, mm)
Zeitfenster: At study visit (single visit)
|
Agreement between AI-derived and rater-derived measurements of corneal center displacement expressed as distance (mm) across 9 gaze positions, assessed by intraclass correlation coefficient (ICC) and Bland-Altman analysis.
|
At study visit (single visit)
|
|
Agreement between AI-derived and rater-derived angular deviation (degrees)
Zeitfenster: At study visit (single visit)
|
Agreement between AI-derived and rater-derived measurements of corneal center displacement expressed as angular deviation (degrees) across 9 gaze positions, assessed by ICC and Bland-Altman analysis.
|
At study visit (single visit)
|
|
Linear association and absolute error vs. rater-derived reference
Zeitfenster: At study visit (single visit)
|
Linear association and absolute error between AI-derived and rater-derived measurements (both distance and angular deviation), assessed by Pearson correlation coefficient and mean absolute error (MAE), respectively.
|
At study visit (single visit)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Correlation between AI-derived metrics (assistant-aided recording) and clinician-assessed 9-gaze grading
Zeitfenster: At study visit (single visit)
|
Correlation between AI-derived eye movement metrics obtained from assistant-aided smartphone recordings and clinician-assessed 9-gaze grading (-4 to +4), assessed using Spearman correlation.
|
At study visit (single visit)
|
|
Correlation between AI-derived metrics (patient self-recorded) and clinician-assessed 9-gaze grading
Zeitfenster: At study visit (single visit)
|
Correlation between AI-derived eye movement metrics obtained from patient self-recorded smartphone videos and clinician-assessed 9-gaze grading (-4 to +4), assessed using Spearman correlation.
|
At study visit (single visit)
|
|
Agreement between AI-derived metrics from patient self-recorded vs. assistant-aided recordings
Zeitfenster: At study visit (single visit)
|
Agreement between AI-derived metrics obtained from patient self-recorded and assistant-aided smartphone videos, assessed using ICC and Bland-Altman analysis.
|
At study visit (single visit)
|
|
Linear association and absolute error: patient self-recorded vs. assistant-aided
Zeitfenster: At study visit (single visit)
|
Linear association and absolute error between AI-derived metrics from patient self-recorded and assistant-aided smartphone videos, assessed using Pearson correlation coefficient and mean absolute error (MAE).
|
At study visit (single visit)
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Neurologische Manifestationen
- Erkrankungen des endokrinen Systems
- Erkrankungen des zentralen Nervensystems
- Erkrankungen des Nervensystems
- Genetische Krankheiten, angeboren
- Autoimmunerkrankungen
- Erkrankungen des Immunsystems
- Augenkrankheiten
- Augenkrankheiten, erblich
- Sehstörungen
- Empfindungsstörungen
- Basedow-Krankheit
- Exophthalmus
- Augenhöhlenerkrankungen
- Kropf
- Hyperthyreose
- Erkrankungen der Hirnnerven
- Schilddrüsenerkrankungen
- Angeborene, erbliche und neonatale Krankheiten und Anomalien
- Pathologische Zustände, Anzeichen und Symptome
- Anzeichen und Symptome
- Graves-Ophthalmopathie
- Augenmotilitätsstörungen
- Schielen
- Diplopie
Andere Studien-ID-Nummern
- THYROSCOPE-EOM-2026-01
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .